☆ 4.7 Meeting Abstract

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

ANNALS OF ONCOLOGY (2019)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 30, Issue -, Pages 77-77

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdz094

Keywords

-

Categories

Oncology

Funding

  1. Bristol-Myers Squibb

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.